The stock market has enjoyed a significant run in 2025. The S&P 500 was last seen up about 17% YTD and was less than 1% under its all-time high heading into year-end. Many investors have already started positioning their assets for 2026. Other investors have procrastinated about positioning their capital and assets even as Wall Street’s consensus is calling for double-digit gains next year. Maybe it’s time for some new investment ideas in well-known stocks (blue chips so to speak).
Oggonomics reviews the daily flow of Wall Street analyst research reports each morning. Most of the new Buy and Outperform ratings come with 8% to 12% implied upside. Tuesday’s top analyst calls featured multiple blue chip stocks with stronger expectations that the typical analyst upside targets.
Investors should always keep in mind that no single analyst report should ever be the sole basis to buy or sell a stock. Just keep in mind that analysts sometimes get their thesis wrong, and fundamentals can change in the blink of an eye.
The analyst ratings and price targets mentioned in this report are from each firm mentioned by name. Oggonomics does not maintain any formal ratings and price targets on any of the stocks in this report. Also keep in mind that no analyst reports come with assured outcomes, and no money-back guarantees are even issued if the thesis doesn’t hold up or if investors lose money.
Agilent Technologies, Inc. (NYSE: A) was reinstated with a Buy rating and $170 price target at Goldman Sachs. Its prior close was $142.44 ahead of the call. Agilent’s stock was last seen up just 6% so far in 2025, and its 52-week range is $96.23 to $160.27.
Cardinal Health, Inc. (NYSE: CAH) was started as Overweight with a $243 price target at Barclays, Cardinal Health closed at $198.88 ahead of the call. This stock was actually up 69% so far in 2025, so this is a continued bullish stock if Barclays is right.
Colgate-Palmolive Company (NYSE: CL) was raised to Outperform with a $88 price target at RBC Capital Markets in an “oversold valuation” call. Colgate-Palmolive closed at $76.11 ahead of the call and the consumer products company has a 52-week range of $74.55 to $100.18.
Delta Air Lines, Inc. (NYSE: DAL) was started as Outperform with a $80 price target (versus $67.00) at BMO Capital Markets. The legacy air carrier has a 52-week range of $$34.74 to $69.98.
Micron Technology, Inc. (NASDAQ: MU) has been in the news over discontinuing a legacy DRAM operation to focus on higher-margin AI-chip related products. HSBC started Micron with a Buy rating and assigned a $330 price target. Micron was last seen closer to $247.
Otis Worldwide Corp. (NYSE: OTIS) has had a rough 2025 as its shares were down 6% so far in 2025. BNP Paribas believes it has more room to rise in 2026. The firm raised Otis to Outperform with a $105.00 price target. Otis has a 52-week range of $84.25 to $106.83.
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was started as Overweight at Barclays with a $35 price target. Teva closed at $28.32 ahead of the call and has a 52-week range of $12.47 to $29.10.
United Airlines Holdings, Inc. (NYSE: UAL) was started as Outperform with a $125 target at BMO Capital Markets. United closed at $104.50 ahead of the call with a 52-week range of $52.00 to $116.00.
Viatris Inc. (NASDAQ: VTRS) was started with an Overweight rating and $15 target (versus $11.09 prior close) at Barclays. Its market cap is over $12 billion and the company just recently signed agreements with Biocon on a $815 million stake sale.
Viking Holdings Ltd. (NYSE: VIK) is well-known for its river cruises for adults. Viking was raised to Buy from Neutral with a $78 price target at Goldman Sachs. Its 52-week range is $31.79 to $68.60.
